biostudies-literatureUnknown105(2)Iori APAlexion Pharma ItalyRavulizumab is a second-generation C5i engineered from eculizumab to achieve immediate, complete, and sustained inhibition of terminal complement activity in PNH. The REACTION observational cohort study describes the effectiveness and tolerability of ravulizumab in Italian patients who were previously treated with eculizumab. Eighty-one PNH patients were enrolled in this study. The primary endpoint was the percentage change in lactate dehydrogenase (LDH) from baseline to the end of observation (52 weeks follow-up). Among secondary endpoints, transfusion avoidance, breakthrough hemolysis (BTH) and patients' quality of life (QoL) were evaluated. The median (25-75 percentiles) percentage change in LDH at 52 weeks follow-up was -2.6 (-11.5-13.4) U/L, with 92.3% of the patients presenting LDH wAnnals of hematology50https://www.ebi.ac.uk/biostudies/studies/S-EPMC12823630biostudies-literatureReal life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study.PMC12823630De Vivo ARapezzi DGasparri GCassanelli FSpedini PCiceri FAmico VAmendola ABeggiato EFattizzo BUrbano TAMarano LMetafuni EFiguera ADi Bona ESica SSottana FLanza FCabibbo SClissa CRaso SCaocci GOri ARambaldi ADanesin CGreve MBCignetti AIori APFioritoni FCarini FSelleri CDi Renzo NBarcellini WCampolo BLongu FTucci AfalseReal life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study.Ravulizumab is a second-generation C5i engineered from eculizumab to achieve immediate, complete, and sustained inhibition of terminal complement activity in PNH. The REACTION observational cohort study describes the effectiveness and tolerability of ravulizumab in Italian patients who were previously treated with eculizumab. Eighty-one PNH patients were enrolled in this study. The primary endpoint was the percentage change in lactate dehydrogenase (LDH) from baseline to the end of observation (52 weeks follow-up). Among secondary endpoints, transfusion avoidance, breakthrough hemolysis (BTH) and patients' quality of life (QoL) were evaluated. The median (25-75 percentiles) percentage change in LDH at 52 weeks follow-up was -2.6 (-11.5-13.4) U/L, with 92.3% of the patients presenting LDH w2026-01-01T00:00:00Z2026 Jan2026-07-16T09:44:08.492Z2026-07-09T10:47:11.235ZS-EPMC128236304156605410.1007/s00277-026-06792-w